This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.rt.com/russia/514399-sputnikv-lancet-coronavirus-effective-ertl/

The article has changed 3 times. There is an RSS feed of changes available.

Version 1 Version 2
‘Really good news’: Vaccine expert hails trial results of Russia’s coronavirus vaccine Sputnik V published in Lancet ‘Really good news’: Vaccine expert hails trial results of Russia’s coronavirus vaccine Sputnik V published in Lancet
(about 1 month later)
Results of the Phase III clinical study of Russia’s Sputnik V coronavirus jab should dispel any skepticism and help the global fight against Covid-19, Dr. Hildegunt Ertl from the Wistar Institute for vaccine research told RT.Results of the Phase III clinical study of Russia’s Sputnik V coronavirus jab should dispel any skepticism and help the global fight against Covid-19, Dr. Hildegunt Ertl from the Wistar Institute for vaccine research told RT.
Trial results, published on Tuesday in the Lancet – the UK’s most prestigious medical journal – as a peer-reviewed study, show the vaccine is over 91 percent effective in all age groups, including the elderly most at risk of death from Covid-19, and 100 percent effective in preventing the severe cases of the disease.Trial results, published on Tuesday in the Lancet – the UK’s most prestigious medical journal – as a peer-reviewed study, show the vaccine is over 91 percent effective in all age groups, including the elderly most at risk of death from Covid-19, and 100 percent effective in preventing the severe cases of the disease.
“That’s really good news,” Dr. Ertl told RT from Philadelphia, Pennsylvania. “We want to stop people ending up in the hospital and dying, and [Sputnik V] clearly achieves that.”“That’s really good news,” Dr. Ertl told RT from Philadelphia, Pennsylvania. “We want to stop people ending up in the hospital and dying, and [Sputnik V] clearly achieves that.”
Commenting on the study, the Lancet editors noted that any criticism of Sputnik V for “unseemly haste, corner cutting, and an absence of transparency” is now moot, because “the outcome reported here is clear and the scientific principle of vaccination is demonstrated,” clearing the Russian-made vaccine for the fight against Covid-19.Commenting on the study, the Lancet editors noted that any criticism of Sputnik V for “unseemly haste, corner cutting, and an absence of transparency” is now moot, because “the outcome reported here is clear and the scientific principle of vaccination is demonstrated,” clearing the Russian-made vaccine for the fight against Covid-19.
Dr. Ertl also thinks that skepticism about the vaccine was based on the early results from a very small initial trial. The Lancet published those results in September 2020, just over a month after Sputnik V was first registered. Now that they’ve been confirmed by the Phase III study, “I think the criticism should subside,” the researcher told RT.Dr. Ertl also thinks that skepticism about the vaccine was based on the early results from a very small initial trial. The Lancet published those results in September 2020, just over a month after Sputnik V was first registered. Now that they’ve been confirmed by the Phase III study, “I think the criticism should subside,” the researcher told RT.
Sputnik V can also be stored for months in ordinary refrigerators, while the other vaccines with similar effectiveness require extreme cold storage, which makes them “close to impossible to distribute in less developed countries,” the German-born researcher noted. Other vaccines are also more expensive, whereas Sputnik V costs about $10.Sputnik V can also be stored for months in ordinary refrigerators, while the other vaccines with similar effectiveness require extreme cold storage, which makes them “close to impossible to distribute in less developed countries,” the German-born researcher noted. Other vaccines are also more expensive, whereas Sputnik V costs about $10.
“That’s really crucial right now, for we are facing globally distribution issues, which need to be addressed, and Sputnik will help there,” Dr. Ertl said. She also expressed hope that the world could put politics aside and have as many manufacturers around the world produce as many doses of effective vaccines as possible, in order to end the pandemic.“That’s really crucial right now, for we are facing globally distribution issues, which need to be addressed, and Sputnik will help there,” Dr. Ertl said. She also expressed hope that the world could put politics aside and have as many manufacturers around the world produce as many doses of effective vaccines as possible, in order to end the pandemic.
The Russian Direct Investment Fund (RDIF), which sponsored the development of Sputnik V, has already reached out to the pharmaceutical industries in several countries in Asia and Latin America, hoping to establish partnerships to produce the vaccine locally.The Russian Direct Investment Fund (RDIF), which sponsored the development of Sputnik V, has already reached out to the pharmaceutical industries in several countries in Asia and Latin America, hoping to establish partnerships to produce the vaccine locally.
The Wistar Institute in Philadelphia specializes in cancer, immunology and infectious disease research. Dr. Ertl has worked there since 1987, becoming a full professor in 1996. She also teaches at the University of Pennsylvania School of Medicine and the Children’s Hospital of Philadelphia.The Wistar Institute in Philadelphia specializes in cancer, immunology and infectious disease research. Dr. Ertl has worked there since 1987, becoming a full professor in 1996. She also teaches at the University of Pennsylvania School of Medicine and the Children’s Hospital of Philadelphia.
Think your friends would be interested? Share this story!Think your friends would be interested? Share this story!
Dear readers and commenters,
We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.
Sorry for the inconvenience, and looking forward to your future comments,
RT Team.